Monitor Genmab's upcoming quarterly report for actual royalty revenue recognition and any changes to DARZALEX sales guidance or competitive dynamics (e.g., biosimilar entry).
Price Chart
Executive Summary
Genmab reported Q3 2026 worldwide net trade sales of DARZALEX (daratumumab) of USD 4,239 million, with USD 2,528 million in the U.S. and USD 1,711 million in the rest of the world. Genmab receives royalties on these sales from Johnson & Johnson (Janssen). The filing is a routine quarterly sales update with no other financial or operational disclosures.
Key Facts
- Worldwide net trade sales of DARZALEX in Q3 2026 totaled USD 4,239 million
- U.S. net trade sales were USD 2,528 million
- Rest of world net trade sales were USD 1,711 million
- Genmab receives royalties on worldwide net sales from Johnson & Johnson (Janssen Biotech, Inc.)
Financial Impact
Q3 2026 DARZALEX sales of USD 4,239 million; Genmab's royalty revenue is not disclosed in this filing
Risk Factors
- No guidance or forward-looking financials provided in this filing
- Royalty revenue to Genmab is not disclosed; actual impact on Genmab's financials is unknown from this filing alone
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001434265-26-000136 |
| Document: gmab_20261013x6k.htm | 0001434265-26-000136 |
| Document: 0001434265-26-000136-index-headers.html | 0001434265-26-000136 |
| Document: 0001434265-26-000136-index.html | 0001434265-26-000136 |
| Document: 0001434265-26-000136.txt | 0001434265-26-000136 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 2d ago | 6-K | $42.64 | awaiting T+1 | — | $43.79 (+2.70%) |
Oct 13, 2026 13d ago | 6-K | $36.57 $36.89 | ▲ +0.88% | ▲ +1.96% | $43.79 (+19.74%) |
Oct 7, 2026 18d ago | 6-K | $36.65 $36.05 | ▼ −1.64% | ▼ −1.21% | $43.79 (+19.48%) |
Oct 5, 2026 20d ago | SC 13G | $37.80 $36.65 | ▼ −3.04% | ▼ −2.80% | $43.79 (+15.85%) |
Oct 5, 2026 20d ago | 6-K | $38.48 $37.80 | ▼ −1.77% | ▼ −2.32% | $43.79 (+13.80%) |
Oct 2, 2026 23d ago | 6-K | $34.75 $38.48 | ▲ +10.73% | ▲ +10.06% | $43.79 (+26.01%) |
Sep 29, 2026 26d ago | 6-K | $35.57 $35.68 | ▲ +0.30% | ▲ +0.50% | $43.79 (+23.11%) |
Sep 24, 2026 4w ago | 6-K | $34.83 $35.32 | ▲ +1.41% | ▲ +0.86% | $43.79 (+25.72%) |
Sep 8, 2026 6w ago | 6-K | $33.53 $33.04 | ▼ −1.46% | ▼ −1.00% | $43.79 (+30.60%) |
Aug 12, 2026 10w ago | 6-K | $31.42 $31.34 | ▼ −0.25% | ▼ −0.95% | $43.79 (+39.37%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers